First made-in-India intra-nasal COVID vaccine to be launched on R-Day
The nasal vaccine can be taken after six months of the second dose
Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC on 26th January, the company’s CMD Krishna Ella announced.
The vaccine manufacturer had already received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month for the nasal vaccine, the first of its kind in India.
“Our nasal vaccine will be officially launched on Republic Day on January 26,” said Ella, while participating in a session during the eighth edition of the India International Science Festival (IISF) that began at the Maulana Azad National Institute of Technology (MANIT).
The session was titled ‘Face-to-Face with New Frontiers in Science.’
The company had earlier announced that it would price the intra-nasal vaccine at Rs 325 per shot for procurement by the government, and Rs 800 per shot for private vaccination centres.
As per the vaccine manufacturer, the nasal route has potential for vaccination due to the organised immune system of the nasal mucosa. Thus, intra-nasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection and transmission.
The nasal vaccine can be taken after six months of the second dose.
Edits by EP News Bureau